Cargando…

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therapeutic option for cancer treatment. However, modulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Juwon, Han, Youngjin, Wang, Wenyu, Jo, HyunA, Kim, Heeyeon, Kim, Soochi, Yang, Kyung-Min, Kim, Seong-Jin, Dhanasekaran, Danny N., Song, Yong Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393583/ https://www.ncbi.nlm.nih.gov/pubmed/34439774 http://dx.doi.org/10.3390/biom11081107

Ejemplares similares

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer
por: Wang, Wenyu, et al.
Publicado: (2020)

Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer
por: Han, Youngjin, et al.
Publicado: (2019)

Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer
por: Kim, Soochi, et al.
Publicado: (2018)

Metabolic Syndrome as a Risk Factor of Endometrial Cancer: A Nationwide Population-Based Cohort Study of 2.8 Million Women in South Korea
por: Jo, HyunA, et al.
Publicado: (2022)

Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer
por: Wang, Wenyu, et al.
Publicado: (2022)

Risk of female-specific cancers according to obesity and menopausal status in 2•7 million Korean women: Similar trends between Korean and Western women
por: Park, In Sil, et al.
Publicado: (2021)

Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro
por: Kim, Soochi, et al.
Publicado: (2016)

Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment
por: Wang, Wenyu, et al.
Publicado: (2020)

Tumor evolution and chemoresistance in ovarian cancer
por: Kim, Soochi, et al.
Publicado: (2018)

Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway
por: Kim, Boyun, et al.
Publicado: (2017)

Enhanced Susceptibility to Breast Cancer in Korean Women With Elevated Serum Gamma-Glutamyltransferase Levels: A Nationwide Population-Based Cohort Study
por: Seol, Aeran, et al.
Publicado: (2021)

Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hye Ryeon, et al.
Publicado: (2022)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer
por: Kim, Soochi, et al.
Publicado: (2016)

Piceatannol Is Superior to Resveratrol at Suppressing Adipogenesis in Human Visceral Adipose-Derived Stem Cells
por: Park, In Sil, et al.
Publicado: (2021)

Metagenomic Analysis of Serum Microbe-Derived Extracellular Vesicles and Diagnostic Models to Differentiate Ovarian Cancer and Benign Ovarian Tumor
por: Kim, Se Ik, et al.
Publicado: (2020)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

Machine Learning Approaches for Assessing Risk Factors of Adrenal Insufficiency in Patients Undergoing Immune Checkpoint Inhibitor Therapy
por: Kim, Woorim, et al.
Publicado: (2023)

Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
por: Lee, Seon-Mi, et al.
Publicado: (2023)

Endocrine side effects of immune checkpoint inhibitors
por: Cardona, Zulma, et al.
Publicado: (2023)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Bae, Seongman, et al.
Publicado: (2021)

Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer
por: Luo, LingJie, et al.
Publicado: (2023)

PGC1α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells
por: Kim, Boyun, et al.
Publicado: (2017)

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
por: Lee, Kyung-Ann, et al.
Publicado: (2019)

Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea
por: Hyun, Jae-Won, et al.
Publicado: (2022)

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Lee, Amy Junghyun, et al.
Publicado: (2021)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
por: Kim, Jehun, et al.
Publicado: (2022)

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
por: Jo, Hyunji, et al.
Publicado: (2022)

Magnetic Resonance Colonography Enables the Efficacy Assessment of Immune Checkpoint Inhibitors in an Orthotopic Colorectal Cancer Mouse Model()()
por: Chae, Yeon Ji, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy
por: Dhanasekaran, Maheswaran, et al.
Publicado: (2023)

Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
por: Seto, Tiffany, et al.
Publicado: (2019)

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer
por: Kang, Da Hyun, et al.
Publicado: (2022)

The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy
por: Yoon, Sang Jun, et al.
Publicado: (2021)

Evaluating Tumor Evolution via Genomic Profiling of Individual Tumor Spheroids in a Malignant Ascites
por: Kim, Sungsik, et al.
Publicado: (2018)

Author Correction: Evaluating Tumor Evolution via Genomic Profiling of Individual Tumor Spheroids in a Malignant Ascites
por: Kim, Sungsik, et al.
Publicado: (2018)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
por: Kim, Ryul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_salin317l99c6siks7b9g3u3hl